BeiGene Valuation
Is BGNE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BGNE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BGNE ($190.51) is trading below our estimate of fair value ($509.77)
Significantly Below Fair Value: BGNE is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BGNE?
Key metric: As BGNE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BGNE's PS Ratio? | |
|---|---|
| PS Ratio | 6.2x |
| Sales | CN¥23.51b |
| Market Cap | CN¥146.66b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.7x |
| Enterprise Value/EBITDA | -24.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BGNE's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 10.7x | ||
NTRA Natera | 14.4x | 12.4% | US$22.1b |
ALNY Alnylam Pharmaceuticals | 15.1x | 22.4% | US$31.6b |
HZNP Horizon Therapeutics | 7.3x | 8.3% | US$26.6b |
UTHR United Therapeutics | 6x | 7.7% | US$16.6b |
BGNE BeiGene | 6.2x | 19.5% | US$20.2b |
Price-To-Sales vs Peers: BGNE is good value based on its Price-To-Sales Ratio (6.2x) compared to the peer average (11.8x).
Price to Sales Ratio vs Industry
How does BGNE's PS Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: BGNE is good value based on its Price-To-Sales Ratio (6.2x) compared to the US Biotechs industry average (9.7x).
Price to Sales Ratio vs Fair Ratio
What is BGNE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.2x |
| Fair PS Ratio | 11.4x |
Price-To-Sales vs Fair Ratio: BGNE is good value based on its Price-To-Sales Ratio (6.2x) compared to the estimated Fair Price-To-Sales Ratio (11.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$190.51 | US$277.61 +45.7% | 15.9% | US$376.00 | US$152.00 | n/a | 22 |
| Nov ’25 | US$204.21 | US$276.99 +35.6% | 15.1% | US$345.00 | US$152.00 | n/a | 22 |
| Oct ’25 | US$230.98 | US$274.14 +18.7% | 16.0% | US$345.00 | US$152.00 | n/a | 22 |
| Sep ’25 | US$191.78 | US$272.96 +42.3% | 16.7% | US$345.00 | US$152.00 | n/a | 21 |
| Aug ’25 | US$162.29 | US$264.27 +62.8% | 19.0% | US$345.00 | US$152.00 | n/a | 20 |
| Jul ’25 | US$144.89 | US$267.01 +84.3% | 18.2% | US$345.00 | US$152.00 | n/a | 21 |
| Jun ’25 | US$148.85 | US$267.01 +79.4% | 18.2% | US$345.00 | US$152.00 | n/a | 21 |
| May ’25 | US$156.53 | US$268.40 +71.5% | 19.2% | US$345.00 | US$152.00 | n/a | 21 |
| Apr ’25 | US$159.23 | US$269.36 +69.2% | 18.3% | US$345.00 | US$161.00 | n/a | 21 |
| Mar ’25 | US$165.02 | US$270.08 +63.7% | 17.4% | US$345.00 | US$171.40 | n/a | 21 |
| Feb ’25 | US$149.93 | US$282.99 +88.7% | 15.1% | US$359.00 | US$196.00 | n/a | 19 |
| Jan ’25 | US$180.36 | US$285.19 +58.1% | 15.3% | US$359.00 | US$196.00 | n/a | 19 |
| Dec ’24 | US$187.49 | US$285.19 +52.1% | 15.3% | US$359.00 | US$196.00 | n/a | 19 |
| Nov ’24 | US$181.30 | US$287.65 +58.7% | 16.4% | US$359.00 | US$180.18 | US$204.21 | 19 |
| Oct ’24 | US$179.87 | US$293.49 +63.2% | 13.5% | US$359.00 | US$196.00 | US$230.98 | 20 |
| Sep ’24 | US$208.92 | US$295.74 +41.6% | 13.1% | US$359.00 | US$196.00 | US$191.78 | 21 |
| Aug ’24 | US$206.54 | US$299.25 +44.9% | 14.8% | US$400.00 | US$196.00 | US$162.29 | 21 |
| Jul ’24 | US$178.30 | US$308.39 +73.0% | 12.9% | US$400.00 | US$196.00 | US$144.89 | 19 |
| Jun ’24 | US$223.48 | US$316.38 +41.6% | 8.5% | US$400.00 | US$263.30 | US$148.85 | 20 |
| May ’24 | US$259.98 | US$310.77 +19.5% | 9.6% | US$400.00 | US$262.00 | US$156.53 | 20 |
| Apr ’24 | US$215.53 | US$307.73 +42.8% | 10.7% | US$400.00 | US$230.10 | US$159.23 | 21 |
| Mar ’24 | US$235.88 | US$310.06 +31.4% | 10.9% | US$400.00 | US$230.10 | US$165.02 | 20 |
| Feb ’24 | US$254.28 | US$300.79 +18.3% | 14.9% | US$400.00 | US$213.00 | US$149.93 | 19 |
| Jan ’24 | US$219.94 | US$264.98 +20.5% | 18.1% | US$400.00 | US$203.13 | US$180.36 | 18 |
| Dec ’23 | US$194.57 | US$263.21 +35.3% | 18.6% | US$400.00 | US$203.13 | US$187.49 | 18 |
| Nov ’23 | US$169.43 | US$264.55 +56.1% | 18.8% | US$400.00 | US$200.00 | US$181.30 | 18 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Spectrum Pharmaceuticals
US$209.9m
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.
SPPI
US$1.03
7D
5.3%
1Y
17.0%
IQVIA Holdings
US$36.6b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV
US$201.82
7D
4.7%
1Y
-4.8%
Collegium Pharmaceutical
US$966.2m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$29.96
7D
1.3%
1Y
15.1%